ClinicalTrials.gov
ClinicalTrials.gov Menu

Cupping and Serkangabin Versus Conventional Migraine Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01476930
Recruitment Status : Completed
First Posted : November 22, 2011
Last Update Posted : November 24, 2014
Sponsor:
Information provided by (Responsible Party):
Birjand University of Medical Sciences

November 14, 2011
November 22, 2011
November 24, 2014
June 2008
September 2009   (Final data collection date for primary outcome measure)
frequency of migraine attacks per week [ Time Frame: 2 weeks after first presentation ]
endpoints evaluated in both study groups 2 weeks after first presentation and receiving treatment protocols
Same as current
Complete list of historical versions of study NCT01476930 on ClinicalTrials.gov Archive Site
  • severity of migraine attacks [ Time Frame: 2 weeks after first presentation ]
    severity of migraine attacks evaluated 2 weeks after first presentation in two study groups
  • duration of migraine attacks [ Time Frame: 2 weeks after first presentation ]
    duration of migraine attacks evaluated 2 weeks after first presentationin two study groups
  • severity of migraine attacks [ Time Frame: 1 month after first presentation ]
    severity of migraine attacks evaluated 1 month after first presentation in two study groups
  • severity of migraine attacks [ Time Frame: 3 months after first presentation ]
    severity of migraine attacks evaluated 3 months after first presentation in two study groups
  • severity of migraine attacks [ Time Frame: 6 months after first presentation ]
    severity of migraine attacks evaluated 6 months after first presentation in two study groups
  • duration of migraine attacks [ Time Frame: 1 month after first presentation ]
    duration of migraine attacks evaluated 1 month after first presentation in two study groups
  • duration of migraine attacks [ Time Frame: 3 months after first presentation ]
    duration of migraine attacks evaluated 3 months after first presentation in two study groups
  • duration of migraine attacks [ Time Frame: 6 months after first presentation ]
    duration of migraine attacks evaluated 6 months after first presentation in two study groups
  • frequency of migraine attacks [ Time Frame: 1 month after first presentation ]
    frequency of migraine attacks evaluated 1 month after first presentation in two study groups
  • frequency of migraine attacks [ Time Frame: 3 months after first presentation ]
    frequency of migraine attacks evaluated 3 months after first presentation in two study groups
  • frequency of migraine attacks [ Time Frame: 6 months after first presentation ]
    frequency of migraine attacks evaluated 6 months after first presentation in two study groups
Same as current
Not Provided
Not Provided
 
Cupping and Serkangabin Versus Conventional Migraine Treatment
Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial
Migraine is the most common recurrent headache. Current therapy of migraine headache consists of multiple drug groups for control of attack and prophylaxis against recurrent attacks. Emerging alternative medicine worldwide led investigators to evaluate the efficacy of cupping therapy plus SERKANGABIN syrup in treatment of migraine headache. Severity, duration and frequency of attacks of migraine headache evaluated in two groups during six months from presentation.
In a randomized controlled trial investigators randomly assigned 76 patients with migraine to cupping therapy plus SERKANGABIN or to receive conventional medical treatment. The use of CAM in migraine is a growing phenomenon. Migraine patients seek and explore both conventional and CAM approaches. Wet cupping is an ancient medical technique still used in several contemporary societies. It is being used in management of hypertension, diabetes mellitus, and headaches, renal and biliary stones and for maintaining health. Little experimental study has been devoted to test its efficacy to treat migraine headache. Investigators planned this study for evaluation of therapeutic efficacy of wet cupping and an Iranian traditional medicine preparation, SERKANGABIN in treatment of migraine headache compared with current medicine protocols. SERKANGABIN is a preparation of honey, vinegar and distilled mint water that in traditional Iranian medicine is believed to have therapeutic effects in many diseases (diabetes mellitus, hypertension, hyperlipidemia, osteoarthritis, chronic obstructive airway disease, interstitial lung disease, hepatitis, fatty liver, ischemic heart disease, migraine, cerebrovascular diseases)
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Migraine Headache
  • Procedure: cupping and serkangabin syrup
    wet cupping serkangabin syrup
  • Drug: conventional migraine drug treatment
    nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
  • Experimental: cupping serkangabin
    migraine cases treated by cupping and serkangabin syrup
    Intervention: Procedure: cupping and serkangabin syrup
  • Active Comparator: conventional
    migraine cases treated by conventional drug treatment protocols
    Intervention: Drug: conventional migraine drug treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
391
Same as current
October 2011
September 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • migraine headache with or without aura

Exclusion Criteria:

  • uncontrolled hypertension
  • ischemic heart disease
  • cardiac arrhythmia or symptomatic Wolff-Parkinson-White syndrome
  • previous stroke or transient ischemic attack
  • severe liver or renal impairment
  • any other severe or disabling medical condition
  • history of alcohol or analgesic or psychotropic drug abuse
  • contraindication to or known hypersensitivity to study drugs
  • current use or use in the previous 2 weeks of MAO-inhibitors
  • a pain disorder other than migraine as the primary presenting problem
  • current psychological treatment, psychiatric disorder needing immediate or priority treatment
  • current or planned breast feeding or pregnancy or unwillingness to use an established contraceptive method
  • non compliance of patients
  • not presenting at times determined for treatment and evaluation
Sexes Eligible for Study: All
15 Years to 50 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Iran, Islamic Republic of
 
 
NCT01476930
n231
n231hej ( Other Grant/Funding Number: birjand university of medical sciences )
Yes
Not Provided
Not Provided
Birjand University of Medical Sciences
Birjand University of Medical Sciences
Not Provided
Study Chair: mohammad khodashenas roudsari, M.D. assistant proffessor of internal medicine
Birjand University of Medical Sciences
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP